Investor Relations

Latest News

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

Event icon

Coporate Presentation

Mineralys Corporate Overview March 2023

Presentation icon

Latest Event

Fourth Quarter and Full Year 2022 Earnings Call

Latest Financial Results

FY 2022

Fiscal Year Ended Dec 31, 2022

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Mineralys Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company committed to developing treatments for diseases that are driven by abnormally elevated aldosterone. The Company’s clinical-stage product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, licensed from Mitsubishi Tanabe Pharma Corporation (“Mitsubishi Tanabe”), that is being investigated for the treatment of hypertension. The Company has completed a Phase 2 proof-of-concept study in patients with uncontrolled hypertension and has plans for the continued research and development of lorundrostat in hypertension and other potential indications. The Company was incorporated as a Delaware corporation in May 2019, and it is headquartered in Radnor, Pennsylvania.

Contact Information


Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd
Suite F200
Radnor, PA 19087
United States
Toll-Free: 888-378-6240

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, New York 11219
United States
T: 800-937-5449
F: 718-236-2641


Elixir Health Public Relations
Tom Weible
T: 515-707-9678